{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:32:04Z","timestamp":1765546324546,"version":"3.40.5"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.leukres.2018.05.007","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T16:43:59Z","timestamp":1527612239000},"page":"67-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7118-624X","authenticated-orcid":false,"given":"C.","family":"Kelaidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Arana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Marceau-Renaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lazarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Soret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cereja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Letestu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Eclache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lusina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Baran-Marszak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Preudhomme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2018.05.007_bib0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2141.1988.tb04194.x","article-title":"Antilymphocyte globulin for myelodysplastic syndrome?","volume":"68","author":"Tichelli","year":"1988","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.05.007_bib0010","first-page":"322","article-title":"Autoimmune myelodysplasias","volume":"28","author":"Miescher","year":"1991","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.leukres.2018.05.007_bib0015","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1548::AID-CNCR16>3.0.CO;2-Y","article-title":"Immunosuppressive therapy for hypoplastic myelodysplastic syndrome","volume":"79","author":"Biesma","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2018.05.007_bib0020","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3324\/haematol.13755","article-title":"Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach","volume":"94","author":"Bennett","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.05.007_bib0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJM198301203080301","article-title":"Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial","volume":"308","author":"Champlin","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.05.007_bib0030","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.leukres.2004.03.016","article-title":"Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells","volume":"28","author":"Deeg","year":"2004","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2018.05.007_bib0035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2141.1982.tb02817.x","article-title":"Results of immunosuppression in 170 cases of severe aplastic anaemia. Report of the European Group Of Bone Marrow Transplant (EGBMT)","volume":"51","author":"Gluckman","year":"1982","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.05.007_bib0040","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3324\/haematol.2013.095786","article-title":"Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood","volume":"99","author":"Yoshimi","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.05.007_bib0045","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2141.1997.4423249.x","article-title":"Antithymocyte globulin for patients with myelodysplastic syndrome","volume":"99","author":"Molldrem","year":"1997","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.05.007_bib0050","doi-asserted-by":"crossref","first-page":"156","DOI":"10.7326\/0003-4819-137-3-200208060-00007","article-title":"Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes","volume":"137","author":"Molldrem","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.leukres.2018.05.007_bib0055","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1038\/sj.leu.2403124","article-title":"Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes","volume":"17","author":"Yazji","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.05.007_bib0060","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1046\/j.1365-2141.2003.04136.x","article-title":"A pilot study of antithymocyte globulin (ATG) in the treatment of patients with \u2018low-risk\u2019 myelodysplasia","volume":"120","author":"Killick","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.05.007_bib0065","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.leu.2403239","article-title":"A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes","volume":"18","author":"Stadler","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.05.007_bib0070","first-page":"667","article-title":"Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes","volume":"91","author":"Broliden","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.05.007_bib0075","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/sj.leu.2404747","article-title":"Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin","volume":"21","author":"Lim","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.05.007_bib0080","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2007.11.9214","article-title":"Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy","volume":"26","author":"Sloand","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.05.007_bib0085","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2010.31.2686","article-title":"Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33\/99","volume":"29","author":"Passweg","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.05.007_bib0090","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2141.2012.09064.x","article-title":"Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome","volume":"157","author":"Kadia","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.05.007_bib0095","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.22184","article-title":"The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression","volume":"87","author":"Xiao","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.05.007_bib0100","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2012.083345","article-title":"A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction","volume":"99","author":"Komrokji","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.05.007_bib0105","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.V100.3.786","article-title":"Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children","volume":"100","author":"Kojima","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.05.007_bib0110","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s12185-013-1468-8","article-title":"Long-term outcome of immunosuppressive therapy for japanese patients with lower-risk myelodysplastic syndromes","volume":"98","author":"Hata","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2018.05.007_bib0115","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2141.2010.08145.x","article-title":"Antithymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study","volume":"149","author":"Scott","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.05.007_bib0120","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1200\/JCO.2010.29.7010","article-title":"Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions","volume":"28","author":"Sloand","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.05.007_bib0125","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1182\/blood-2010-11-314393","article-title":"SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes","volume":"117","author":"Afable","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.05.007_bib0130","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1182\/blood-2013-04-494930","article-title":"STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients","volume":"122","author":"Jerez","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.05.007_bib0135","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1182\/blood-2014-05-574889","article-title":"Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome","volume":"124","author":"Kulasekararaj","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.05.007_bib0140","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood.V124.21.3269.3269","article-title":"Hypoplastic MDS is a distinct clinico-pathological entity with somatic mutations frequent in patients with prior aplastic anaemia with favorable clinical outcome","volume":"124","author":"Hunt","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.05.007_bib0145","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2015.130112","article-title":"Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes","volume":"100","author":"Nazha","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.05.007_bib0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1414799","article-title":"Somatic mutations and clonal hematopoiesis in aplastic anemia","volume":"373","author":"Yoshizato","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.05.007_bib0155","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2011-06-360313","article-title":"Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency","volume":"118","author":"Dickinson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.05.007_bib0160","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/ng.913","article-title":"Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia","volume":"43","author":"Hahn","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2018.05.007_bib0165","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2011-05-356352","article-title":"Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome","volume":"118","author":"Hsu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.05.007_bib0170","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/ng.923","article-title":"Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome)","volume":"43","author":"Ostergaard","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2018.05.007_bib0175","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3324\/haematol.2011.054361","article-title":"Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival","volume":"97","author":"B\u00f6d\u00f6r","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.05.007_bib0180","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-07-517151","article-title":"The evolution of cellular deficiency in GATA2 mutation","volume":"123","author":"Dickinson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.05.007_bib0185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood-2014-06-580340","article-title":"GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia","volume":"125","author":"Ganapathi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.05.007_bib0190","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2015-04-641100","article-title":"Genomic analysis of germ line and somatic variants in familial myelodysplasia\/acute myeloid leukemia","volume":"126","author":"Churpek","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.05.007_bib0195","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplasticsyndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.05.007_bib0200","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.05.007_bib0205","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/0145-2126(94)90036-1","article-title":"Bone marrow cellularity in myeloid stem cell disorders: impact of age correction","volume":"18","author":"Tuzuner","year":"1994","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2018.05.007_bib0210","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/ajcp\/43.4.326","article-title":"Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior iliac crest. A study made from 177 cases of sudden death examined by necropsy","volume":"43","author":"Hartsock","year":"1965","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.leukres.2018.05.007_bib0215","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cyto.b.20525","article-title":"Clinical Cytometry Society. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry","volume":"78","author":"Borowitz","year":"2010","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.leukres.2018.05.007_bib0220","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1309\/AJCPWMWJ7XDNQ3SN","article-title":"HPN-AFC Group. Evaluation of paroxysmal nocturnal hemoglobinuria screening by flow cytometry through multicentric interlaboratory comparison in four countries","volume":"144","author":"Debliquis","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.leukres.2018.05.007_bib0225","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.05.007_bib0230","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.leukres.2018.05.007_bib0235","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.leukres.2018.05.007_bib0240","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. B"},{"key":"10.1016\/j.leukres.2018.05.007_bib0245","first-page":"185","article-title":"Asymptotically efficient rank invariant test procedures","volume":"1972","author":"Peto","year":"2016","journal-title":"J. R. Stat. Soc. Ser. A (Gen.)"},{"key":"10.1016\/j.leukres.2018.05.007_bib0250","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood.V100.5.1570.h81702001570_1570_1574","article-title":"HLADR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome","volume":"100","author":"Saunthararajah","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.05.007_bib0255","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood-2004-05-2017","article-title":"Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome","volume":"106","author":"Sloand","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.05.007_bib0260","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2013.286","article-title":"U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618301097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618301097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T03:54:28Z","timestamp":1720324468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618301097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":52,"alternative-id":["S0145212618301097"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.05.007","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}